renal replacement therapy
[용어속성] Treatment
Characteristics and outcomes of hospitalised patients with acute kidney injury and COVID-19
급성신장손상 및 코로나19로 입원한 환자의 특징 및 결과
Research Article
[키워드] Acute kidney injury
Admission
Adult patients
AKI
association
baseline characteristics
Biochemistry
Comorbidities
COVID-19
Critical care
death
Deprivation
Deterioration
diagnosis of COVID-19
disease
Escalation
foundation
hospital
hospitalised patient
Initially
laboratory data
mechanical ventilation
medications
Mortality
multiple organ involvement
observations
outcome
overall mortality
P-value
pandemic
Patient
patients
patients with AKI
patients with COVID-19
presenting
Prevent
Record
renal
renal disease
renal function
renal replacement therapy
replacement therapy
required
respiratory
Result
retrospective
retrospective review
risk
shown
Spread
the disease
Trust
university
with COVID-19
World Health Organisation
[DOI] 10.1371/journal.pone.0241544 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.pone.0241544 PMC 바로가기 [Article Type] Research Article
Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] adjuvant
Administered
Adverse
age
alanine aminotransferase
All study participant
allergy
approved
ARDS
Aspartate transaminase
Aspirin
atorvastatin
benefit
bleeding
block randomization
Breastfeeding
C-reactive protein
characterized
clinical
Clinical deterioration
Clinical improvement
Clinical outcome
Coagulopathy
collected data
computer-generated
conducted
confirmed case
control group
COVID-19
COVID-19 patient
COVID-19 patients
CPK
creatine phosphokinase
Critical
derivative
discharge
dissemination
dose
drug
drug interaction
ECMO
Effect
element
Endotracheal intubation
enrolment
ethical committee
evaluated
examined
excluded
exclusion criteria
Final
Hepatitis
HIV
Hospital admission
hospital discharge
hospitalisation
ICMR
ICU admission
in-hospital mortality
include
Inclusion
India
infected with SARS-CoV-2
Inflammatory marker
interim analysis
liver
management
mechanical ventilation
Medical Science
medication
Mortality
myalgia
National Cancer Institute
New
Non-invasive
number
objective
Open-label
Other
outbreak
outcome
outcomes
pandemic
parallel-group
participant
Patient
patients
Platelet
Pregnancy
Primary outcome
progression
Protease inhibitor
protease inhibitors
protocol
randomised
Randomised control trial
randomised controlled trial
randomize
Randomized
receiving
recruited
recruitment
reference
Registered
registry
renal replacement therapy
respiratory
RT-PCR
Sample size
SARS-CoV-2
SARS-COV-2 infection
secondary outcome
serum
Shock
statin
status
study period
Study protocol
supplementary material
symptom onset
Tablet
therapy
Treatment protocol
Trial
troponin
usual care
website
WHO
written consent
written Informed Consent
[DOI] 10.1186/s13063-020-04840-y PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04840-y PMC 바로가기 [Article Type] Letter
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 1:1
24 hour
Ability
absence
accompany
activity
Administered
administration
Admission
adverse events
Affect
age
alkaline phosphatase
allergy
ALT
alternative hypothesis
ambient
Analysis
ANC
Anti-inflammatory
anticipated
antipyretics
antivirals
Arm
ARMS
assumed
AST
Baltimore
baseline
benefit
blinded
block
block randomization
Blood
breastfeeding women
Bronchoalveolar lavage
calculated
Care
Cellulose
center
Chest
chest X-ray
childbearing potential
clinical
clinical condition
Clinical course
clinical impact
Clinical improvement
Clinical outcome
clinical status
clinical trial
collected
competing
Compliance
concealed
Concentration
Concomitant
conditions
conducted
congestive heart failure
Contraception
Control
control arm
Conventional
Corticosteroids
COVID-19
COVID-19 disease
COVID-19 infection
COVID-19 pandemic
criteria
criterion
Critical
CT scan
current
Day
Declaration of Helsinki
decrease
defined
detect
direct bilirubin
disease
disorder
dissemination
dose
double-blind
drug
Drug administration
drug-drug interaction
drugs
Duration
ECMO
Efficacy
Efficacy and safety
element
eligible
endosomal pH
Enrollment
ethnic group
evaluate
Evidence
exclusion
expected
exploratory endpoint
extracorporeal membrane oxygenation
Face mask
FDA
Fisher
Good
group
handling
harmonization
hematologic
histocompatibility complex
Hospitalization
Hospitalized
hospitalized patient
Hydroxychloroquine
Hypothesis
ICU
IL-6 levels
Imatinib
immunomodulatory
immunomodulatory drugs
IND
information
Informed consent
inhibitory activity
intensive care
intensive care unit
intention to treat
interfere
International Conference
invasive
Invasive mechanical ventilation
investigational agent
investigator
ITT
Laboratory
Last
limit
limitation
liver
Local
lysosomal sequestration
magnitude
matching placebo
mechanical ventilation
men and women
MHC
mononuclear cell
Mortality
nasal
nasopharyngeal
Nasopharyngeal swab
neutrophil count
New
new oxygen use
non-invasive ventilation
non-rebreather mask
not blinded
null hypothesis
number
objective
off-label
off-label use
Oropharyngeal
outcome
outcomes
oxygen
Oxygenation
P450
packaged
PaO
participant
Participants
Patient
patients
patients with ARDS
patients with COVID-19
PBMCs
performed
Pharmacist
Pharmacy
phase 3 study
Placebo
placebo-controlled
Pneumonia
positive COVID-19
Practice
primary analysis
primary endpoint
principal
progression
proportion
protocol
Psychiatric
Radiographic
random number generator
randomised controlled trial
randomization
Randomized
Randomized controlled trial
receive
receiving
recruitment
Regulatory
renal dysfunction
renal replacement therapy
replication of SARS-CoV-2
required
requiring supplemental oxygen
Respiratory illness
respiratory tract
risk
RT-PCR
Safety
Sample size
sarilumab
SARS-CoV
SARS-CoV-2
secondary endpoint
Seizure
Serious Adverse Events
service
severe disease
severity
significance level
Site
Society
stability
Standard of care
status
stratified
study drug
study enrollment
study outcomes
Study protocol
subject
submitted
supplemental oxygen
Support
Suspension
symptomatic
Tablet
temperature
Test
the patient
the primary endpoint
time
TKI
TKI-induced attenuation of vascular leak
TKI-induced prevention and treatment lung inflammation
Tocilizumab
transcriptomics
Treatment
treatment allocation
treatment arm
treatments for COVID-19
Trial
two-sided
tyrosine kinase inhibitor
uncontrolled
university
unstable angina
vasopressors
ventilator
ventilator free days
viral ABL-1 signalling
website
with COVID-19
[DOI] 10.1186/s13063-020-04819-9 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04819-9 PMC 바로가기 [Article Type] Letter
The COVID-19 nephrology compendium: AKI, CKD, ESKD and transplantation
Review
[키워드] Acute kidney injury
AKI
Chronic kidney disease
CKD
consequence
coronavirus disease
COVID-19
Critical care
disease
disparity
equipment
ESKD
high mortality
Immunosuppression
incidence
Increased
International
Kidney disease
management
mechanism
organ systems
outcome
pandemic
Patient
recipient
regimen
renal replacement therapy
seriously ill patients
Surveillance
susceptible
threshold
transplantation
[DOI] 10.1186/s12882-020-02112-0 PMC 바로가기 [Article Type] Review
[DOI] 10.1186/s12882-020-02112-0 PMC 바로가기 [Article Type] Review
Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory Disease
Original Article
[키워드] acute respiratory distress
anticoagulation
apixaban
Atrial fibrillation
benefit
bleeding
bleeding event
coagulation parameter
Coagulation parameters
Coagulopathy
COVID-19
death
Direct
disease
DOACs
Efficacy
evaluate
evaluated
follow-up period
ICU
ICU patient
Ill
incidence
initiated
intensive care
LMWH
low molecular weight
major bleeding event
material
mechanical ventilation
morbidity and mortality
Mortality
novel coronavirus disease
obese
oral anticoagulant
Patient
Prophylaxis
remained
renal dysfunction
renal replacement therapy
required
respiratory
Respiratory disease
Result
retrospective cohort study
Safe
Safety
SARS-CoV-2
seeking
severe COVID-19
severe COVID-19 disease
study period
subsequent
syndrome
thromboembolic disease
Thromboembolic events
thrombosis
treated
Treatment
Trial
unfractionated heparin
Venous Thromboembolism
VTE
[DOI] 10.1055/s-0040-1720962 PMC 바로가기 [Article Type] Original Article
[DOI] 10.1055/s-0040-1720962 PMC 바로가기 [Article Type] Original Article
Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO
Original Article
[키워드] activated
acute phase reactants
Analysis
anti-Xa
aPTT
association
C-reactive protein
Concentration
coronavirus disease
correlated
correlation
COVID-19
COVID-19 patient
CRRT
dosage
ECMO
explained
extracorporeal membrane oxygenation
ferritin
fibrinogen
FVIII
heparin
Heparin resistance
heparin therapeutic range
Linear regression
mandatory
material
monitoring
objective
optical
patients
Prevent
renal replacement therapy
Result
therapeutic
Thrombocytes
Treatment
variable
were measured
were used
[DOI] 10.1055/s-0040-1719083 PMC 바로가기 [Article Type] Original Article
[DOI] 10.1055/s-0040-1719083 PMC 바로가기 [Article Type] Original Article
COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup
Consensus Statement
[키워드] acute disease
acute kidney
Acute kidney injury
AKI
Consensus
coronavirus disease
COVID-19
COVID-19 case
Critically ill
Diagnosis
dialysis
high mortality
hospital resources
In-hospital death
independent risk factor
Infectious diseases
initiative
kidney
limit
management
mechanism
multifactorial
outcome
pathophysiology
Patient
patients with COVID-19
provide
Quality
recommendation
renal replacement therapy
Research
resource
SARS-CoV-2
Scientific community
therapy
[DOI] 10.1038/s41581-020-00356-5 PMC 바로가기 [Article Type] Consensus Statement
[DOI] 10.1038/s41581-020-00356-5 PMC 바로가기 [Article Type] Consensus Statement
Factors influencing liberation from mechanical ventilation in coronavirus disease 2019: multicenter observational study in fifteen Italian ICUs
Research
[키워드] Admission
Analysis
analyzed
ARDS
cardiovascular complications
clinical
competing
complex
Compliance
Complication
contribute
coronavirus disease
Coronavirus disease 2019
Course
COVID-19
COVID-19 patient
death
demonstrated
develop
enrolled
Evolution
Factor
ICU
ICU admission
increasing age
independent risk factor
information
intensive care
Invasive mechanical ventilation
Italian
laboratory data
mechanical ventilation
Mortality
multicenter
multicenter observational study
multiple organ involvement
multivariate logistic regression
Non-pulmonary
observation period
Occurrence
organ dysfunction
outcome
Outcomes, mortality
PaO
Patient
patients with COVID-19
Pneumonia
primary outcome measure
proportion
prospective observational study
Regression model
renal
renal replacement therapy
Respiration, artificial
Respiratory system
Result
risk
risk factor
RRT
severe respiratory failure
SOFA score
the disease
the patient
VAP
variable
ventilator parameters
Ventilator-associated pneumonia
ventilator-free day
were recorded
[DOI] 10.1186/s40560-020-00499-4 PMC 바로가기 [Article Type] Research
[DOI] 10.1186/s40560-020-00499-4 PMC 바로가기 [Article Type] Research